Quick Answer
BIOREGENX, INC. reported Operating Income Loss of -$22.76 million for the year ending 2024.
- BIOREGENX, INC. showed a decrease of -567.8% in Operating Income Loss from 2023 to 2024.
- This data is from BIOREGENX, INC.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2021 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$37.3 thousand | Q2 2022: -$33.3 thousand | Q3 2022: -$2.2 thousand | Q1 2023: -$92.8 thousand | Q2 2023: -$544.6 thousand | Q3 2023: -$2.47 million | Q1 2024: -$3.08 million | Q2 2024: -$1.04 million | Q3 2024: -$327.3 thousand | Q1 2025: -$192.6 thousand | Q2 2025: -$107.3 thousand | Q3 2025: -$8.5 thousand.
- Over the full 4 years of available data (2021 to 2024), BIOREGENX, INC.'s Operating Income Loss has declined by 13,686.1%.
- Historical annual values: Fiscal year 2024: -$22.76 million | Fiscal year 2023: -$3.41 million | Fiscal year 2022: -$78.3 thousand | Fiscal year 2021: -$165.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: